Open AccessHyaluronidase-Facilitated High-Dose Subcutaneous IgG Effectively Controls Parvovirus B19 Infection in a Pediatric Cardiac Transplant Patient With Severe T-Cell Lymphopenia
Author(s) -
Rachel Jesus Cruz,
Joseph Dasso,
Carla Duff,
Diane Krasnopero,
Zsofia Long,
Maryssa Ellison,
Daime Nieves,
Panida Sriaroon,
Alfred AsanteKorang,
Jolán E. Walter
Publication year - 2020
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofaa076
Subject(s) - medicine , viremia , parvovirus , aseptic meningitis , antibody , hyaluronidase , immunology , gastroenterology , meningitis , surgery , virus , biochemistry , chemistry , enzyme
We treated three pediatric cardiac transplant patients with chronic parvovirus viremia with high-dose intravenous immunoglobulin (HD-IVIG). One patient with severe T-cell lymphopenia suffered recurrent viremia and aseptic meningitis, which resolved remarkably when he was switched to high-dose hyaluronidase-facilitated subcutaneous immunoglobulin (HD-SCIG-Hy). We discuss the advantages of HD-SCIG-Hy vs HD-IVIG treatment for similar cases.